Navigation Links
Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
Date:11/20/2008

ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) announced today the global release of MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA are expected to allow researchers to successfully take the next step in their RNAi research with the highest purity and quality siRNA required for RNAi research in animal models. These siRNA are believed to be well suited to target validation and pre-clinical siRNA testing. Intermediate and large synthesis scales and a wide variety of modifications are also available.

"Increasingly, RNAi researchers are utilizing animal models to confirm findings from cell culture based assays or to explore the use of siRNA as a potential therapeutic agent," said Tim Fleming, Director of Global Commercial Marketing at Sigma-Aldrich. "Our goal is to provide an siRNA that is capable of facilitating in vivo siRNA research, with the purity levels required for direct delivery or to be used as an essential part of an overall in vivo formulation strategy."

MISSION(R) In VIVO QUALITY siRNA are processed specifically for in vivo usage. This purification process includes RP-HPLC to ensure a high percentage of full-length product (>94%), dialysis on the annealed product to remove excess salts, 22 micrometer sterile filtration, and finally testing to ensure no endotoxins are present.

In addition, iScale Oligos(TM) synthesis scales can give customers the large quantities of siRNA required for in vivo usage with amounts up to 100mg. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA are available with many of the common modifications used to for tracking or stability, such as FAM, Cy5(TM), and Cy3(TM).

"Sigma-Aldrich's MISSION(R) In VIVO QUALITY siRNAs are used exclusively at BIOO Scientific(TM) for all of our internal in vivo formulation development programs," said Lance Ford, Vice President of Research and Development at BIOO Scientific(TM) Corporation. "Most recently, we have used these siRNAs to with great success to demonstrate the utility of our new in vivo formulation, MaxSuppressor(TM) In Vivo RNA-LANCEr II (catalog #3410-01), in mouse models. BIOO Scientific(TM) Corporation recommends these siRNAs to our all of our customers as they are exceptional siRNAs, offered at a competitive price, with rapid turnaround times and supported by Sigma-Aldrich's professional service."

For more information on the MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, please visit sigma-aldrich.com/invivosirna .

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research
3. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
4. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
5. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
6. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
7. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
8. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
9. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
10. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
11. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... , ... Tunnell Consulting announced today that four of the firm’s ... and Expo , to be held October 29 through November 1 in San Diego ... advance patient therapies.” , The ISPE Annual Meeting and Expo will feature several interactive ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... system, announced it has secured $2M in funding from an impressive group of ... Innovations, and SVG Thrive Fund. With this investment, 3Bar is broadening availability of ...
(Date:8/15/2017)... -- After spending the past two years building a state-of-the-art technology ... now offers this platform to healthcare stakeholders (hospitals, foundations, biopharma companies ... data collection vis a vis their members, under their own brand. ... this offer. ... ...
(Date:8/15/2017)... Boston, MA (PRWEB) , ... August 15, 2017 , ... ... unmet need that has compromised these disciplines for more than half a century. ... cannot be counted. It is widely known that molecular tags developed for this ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):